论文部分内容阅读
非小细胞性肺癌(NSCLC)指鳞癌、腺癌和大细胞癌。在生物学行为和治疗上,它与小细胞性肺癌(SCLC)炯然不同,应首选手术治疗。但是,NSCLC在初诊时约85％的病人已超出了根治性切除的范围,而且手术后复发或转移的病例累见不鲜;放射治疗虽可使一些患者缓解,然难以延长病人的生存期。因此,NSCLC的全身治疗起关键作用。为了继续寻找更为有效的治疗;同时使晚期患者痛苦的症状与体征得到缓解,这是应用化疗的理论基础。近年来,随着有效新药的增多,组成了一些有希望的联合化
Non-small cell lung cancer (NSCLC) refers to squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. In biological behavior and treatment, it is very different from small cell lung cancer (SCLC) and surgical treatment should be the first choice. However, about 85% of patients with NSCLC at the time of initial diagnosis have exceeded the scope of radical resection, and cases of recurrence or metastasis after surgery are not uncommon; while radiation therapy can relieve some patients, it is difficult to extend the survival of patients. Therefore, systemic treatment of NSCLC plays a key role. In order to continue to find more effective treatments, and to relieve the painful symptoms and signs of late patients, this is the theoretical basis for the use of chemotherapy. In recent years, with the increase of effective new drugs, some promising combinations have been formed.